Nicole Calakos, MD, PhD

Duke University

Durham, NC

Mouse model for a novel TorsinA mutation

* Mark A. Gluck, PhD

Rutgers University

Newark, NJ

How dopaminergic medication impacts feedback learning and decision making in Parkinson's patients

* This grant was made possible through the generosity of the Dekker Foundation.

Monica Holmberg, PhD

Umea University

Sweden

Identification of genetic factors responsible for a late-onset form of primary dystonia

Naomi Lubarr, MD

Beth Israel Medical Center

New York, NY

Long Term Clinical outcomes in DYT1 dystonia

Jonathan Mink, MD, PhD

University of Rochester

Rochester, NY

An open-label trail of tetrabenazine for dystonia in cerebral palsy

Martin Niethammer, PhD, MD

The Feinstein Institute for Medical Research

Manahasset, NY

Network-based imaging biomarkers in sporadic dystonia

Louis Ptacek, MD

University of California, San Francisco

San Francisco, CA

Role of MR-1 in exocytosis and dopamine regulation in a transgenic mouse model of DYT8

Rachel Saunder-Pullman, MD, MPH

Beth Israel Medical Center

New York, NY

Johann Hagenah, MD

The University of Luebeck

Luebeck, Germany

Transcranial ultrasonographic evaluation of the basal ganglia in DYT1, DYT11, DYT12 dystonia

David Standaert,MD, PhD

University of Alabama, Birmingham

Birmingham, Al

Antonio Pisani, MD

The University of Rome (Tor Vegata)
Rome, Italy

Effects of selective inactivation of the DYT1 gene on cholinergic function

Kathleen Sweadner, PhD

Massachusetts General Hospital

Boston, MA

Mechanisms of ATP1A3 mutation deficits in rapid onset dystonia parkinsonism

Michele Tagliati, MD

Mount Sinai School of Medicine

New York, NY

The effects of STN-DBS frequency changes on speech in advanced Parkinson's disease

Howard Worman, MD and William T. Dauer, MD

Columbia University

New York, NY

Current focused giving in Dyskinesia